Dose-dependent increase or decrease of somatic intrachromosomal recombination produced by etoposide.
Chromosomal inversions and deletions can occur via somatic intrachromosomal recombination (SICR), a mechanism known to be important in mutagenesis and carcinogenesis. Here, we demonstrate a dose-dependent increase or decrease in SICR inversion frequency both in vivo and in vitro after treatment with etoposide, using the pKZ1 mouse mutagenesis model. pKZ1 mice received a single intraperitoneal injection of etoposide dose ranging from 0.0005 to 50mg/kg. Animals were sacrificed 3 days after treatment and the spleen was analysed for SICR. A significant 1.4-3.1-fold induction of SICR inversion events was detected in pKZ1 mice after treatment with etoposide doses ranging from 0.05 to 50 mg/kg etoposide. However, inversion frequencies after treatment with 0.0005 and 0.005 mg/kg etoposide decreased significantly to 0.67 and 0.43 of the levels observed in control animals, respectively. A pKZ1 mouse hybridoma cell line was exposed to etoposide (1-1000 nM) and a similar pattern of SICR response to that detected in vivo was observed. A significant 2.3-4.6-fold induction of SICR inversions was observed in pKZ1 cells treated with 100 and 1000 nM etoposide. Inversion frequencies after treatment with 1 and 10nM etoposide decreased significantly to 0.31 and 0.5 of the level observed in control cell lines. Our in vitro studies complement our in vivo studies and exclude a kinetic phenomenon as the responsible mechanism of reduction in SICR in response to low dose etoposide. Determination of the exact mechanism and significance of recombination suppression at low doses of etoposide treatment requires further investigation.
Hooker
Antony M
AM
Department of Haematology and Genetic Pathology, Flinders University of South Australia and Flinders Medical Centre, Bedford Park, SA 5042, Australia.
Horne
Rachel
R
Morley
Alexander A
AA
Sykes
Pamela J
PJ
Home
Rachael
R
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002872:Chromosome Deletion; D007446:Chromosome Inversion; D002875:Chromosomes / Q000187:drug effects / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000235:genetics; D005047:Etoposide / Q000494:pharmacology*; D006825:Hybridomas; D051379:Mice; D008822:Mice, Transgenic; D009153:Mutagens / Q000494:pharmacology*; D011995:Recombination, Genetic / Q000187:drug effects*; D001616:beta-Galactosidase / Q000235:genetics
D009153:Mutagens; D005047:Etoposide; D001616:beta-Galactosidase